← All trials
NCT07083765
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2025
- Primary completion
- Jun 30, 2027
- Completion date
- Oct 31, 2027
- First posted
- Jul 24, 2025
- Last posted
- Sep 16, 2025
- Enrollment
- 142
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ablative Solutions, Inc.Lead sponsor
- Piedmont HealthcareOfficial
- University of BaselOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.